Dal Bello G, Maurelli M, Schena D, et al. - Given that dupilumab and cyclosporin are suggested therapies for moderate‐to‐severe atopic dermatitis (AD), researchers conducted this retrospective study to examine drug survival of dupilumab compared with cyclosporin (CsA), the reasons for drug discontinuation, and the predictive parameters of drug survival in daily practice. From January 1, 2019, to April 30, 2020, patients with moderate‐to‐severe AD treated with dupilumab or CsA were included. Participants in the study were adult patients with AD (n = 251) treated with dupilumab (n = 149) or CsA (n = 102). Older age at diagnosis and shorter period of AD were predicting shorter survival of dupilumab. Reasons for CsA withdrawal included adverse reactions in 23.5% of patients, persistent clinical remission in 15.6%, and minimal or missing improvement in 11.7%. Findings suggested that dupilumab has a longer drug survival compared with CsA. Due to adverse effects and/or ineffectiveness, only a small number of dupilumab patients stopped treatment.